ethylmethylhydroxypyridine-succinate and Acute-Disease

ethylmethylhydroxypyridine-succinate has been researched along with Acute-Disease* in 2 studies

Trials

2 trial(s) available for ethylmethylhydroxypyridine-succinate and Acute-Disease

Article	Year
[Efficiency of combined therapy with myocardial cytoprotector mexicor in hypertensive patients with acute cerebrovascular disturbances]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2008, Volume: 14, Issue:4 Sixty hypertensive patients (mean age 64.9 +/- 1.5) with acute ischemic stroke were randomized into 2 groups. Both groups received conventional therapy (Aspirin Cardio, Trental, Prestarium, Arifon), which in the test group was added by Mexicor (0.3 gper day for 3 weeks). Circadian blood pressure (BP) and its variability were monitored in all patients at 1, 5, 10, 14, and 21 days after the stroke. NIH Stroke Scale, the Barthel ADL Index, Rankin Scale, Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) were used for the neurological status assessment. Mexicor was shown to accelerate the systolic and diastolic BP lowering, reduction of BP variability (mainly nocturnal) and improvement of circadian BP profile (more patients showed dipper type hypertension and less - non-dipper, over-dipper and night-peaker patterns, compared with the control group). Mexicor had a positive effect on neurological status, cognitive function and focal neurological deficit severity. Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Cognition; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Neuroprotective Agents; Pyridines; Treatment Outcome	2008
[The effects of mexicor on thrombocyte aggregation, blood viscosity, hemodynamics, and the clinical course of coronary artery disease]. Klinicheskaia meditsina, 2006, Volume: 84, Issue:10 The authors analyze their experience in the application of mexicor, a Russian cytoprotector, in 50patients with chronic coronary artery disease (CAD) and 51 patients with acute coronary syndrome. In additional to cytoprotective action, the use of mexidor in complex therapy of CAD lowers the functional activity of thrombocytes, eliminates high blood viscosity syndrome, and lowers low density lipoprotein cholesterol level. These favorable changes in hemorheological parameters improves myocardial perfusion, lowers the strength and frequency of coronary pain attacks, retards postinfarction left ventricular remodeling, and increases the quality of life of patients with various CAD forms. Topics: Acute Disease; Adult; Angina, Unstable; Blood Platelets; Blood Viscosity; Chronic Disease; Coronary Artery Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines	2006

Article

Year

[Efficiency of combined therapy with myocardial cytoprotector mexicor in hypertensive patients with acute cerebrovascular disturbances].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2008, Volume: 14, Issue:4

Sixty hypertensive patients (mean age 64.9 +/- 1.5) with acute ischemic stroke were randomized into 2 groups. Both groups received conventional therapy (Aspirin Cardio, Trental, Prestarium, Arifon), which in the test group was added by Mexicor (0.3 gper day for 3 weeks). Circadian blood pressure (BP) and its variability were monitored in all patients at 1, 5, 10, 14, and 21 days after the stroke. NIH Stroke Scale, the Barthel ADL Index, Rankin Scale, Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) were used for the neurological status assessment. Mexicor was shown to accelerate the systolic and diastolic BP lowering, reduction of BP variability (mainly nocturnal) and improvement of circadian BP profile (more patients showed dipper type hypertension and less - non-dipper, over-dipper and night-peaker patterns, compared with the control group). Mexicor had a positive effect on neurological status, cognitive function and focal neurological deficit severity.

Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Cognition; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Infusions, Intravenous; Male; Middle Aged; Neuroprotective Agents; Pyridines; Treatment Outcome

2008

[The effects of mexicor on thrombocyte aggregation, blood viscosity, hemodynamics, and the clinical course of coronary artery disease].

Klinicheskaia meditsina, 2006, Volume: 84, Issue:10

The authors analyze their experience in the application of mexicor, a Russian cytoprotector, in 50patients with chronic coronary artery disease (CAD) and 51 patients with acute coronary syndrome. In additional to cytoprotective action, the use of mexidor in complex therapy of CAD lowers the functional activity of thrombocytes, eliminates high blood viscosity syndrome, and lowers low density lipoprotein cholesterol level. These favorable changes in hemorheological parameters improves myocardial perfusion, lowers the strength and frequency of coronary pain attacks, retards postinfarction left ventricular remodeling, and increases the quality of life of patients with various CAD forms.

Topics: Acute Disease; Adult; Angina, Unstable; Blood Platelets; Blood Viscosity; Chronic Disease; Coronary Artery Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines

2006